Together with the Double Intraperitoneal Artificial Pancreas project the Centre welcomes Professor Francis J. Doyle III, Dean of John A. Paulson School of Engineering and Applied Sciences (SEAS), Harvard University, and scholar in chemical engineering to present his latest work on testing algorithms in clinical settings for an artificial pancreas and the future technology for the millions of individuals who are affected by Type 1 diabetes mellitus (T1DM). Prof Doyle has devoted his research to understand and characterize biological systems by a systems engineering approach, contributing to the fields of systems biology and functional biomedical control, while combining computational and experimental work.
Professor Francis J. Doyle III, Dean of John A. Paulson School of Engineering and Applied Sciences (SEAS), Harvard University
Thursday 24 August 2017, 14:00 - 14:45 at NTNU, Trondheim
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease affecting approximately 35 million individuals world-wide, with associated annual healthcare costs in the US estimated to be approximately $15 billion. Current treatment requires either multiple daily insulin injections or continuous subcutaneous (SC) insulin infusion (CSII) delivered via an insulin infusion pump. Both treatment modes necessitate frequent blood glucose measurements to determine the daily insulin requirements for maintaining near-normal blood glucose levels.
More than 30 years ago, the idea of an artificial endocrine pancreas for patients with type 1 diabetes mellitus (T1DM) was envisioned. The closed-loop concept consisted of an insulin syringe, a blood glucose analyzer, and a transmitter. In the ensuing years, a number of theoretical research studies were performed with numerical simulations to demonstrate the relevance of advanced process control design to the artificial pancreas, with delivery algorithms ranging from simple PID, to H-infinity, to model predictive control. With the advent of continuous glucose sensing, which reports interstitial glucose concentrations approximately every minute, and the development of hardware and algorithms to communicate with and control insulin pumps, the vision of closed-loop control of blood glucose is approaching a reality.
In the last 15 years, our research group has been working with medical doctors on clinical demonstrations of feedback control algorithms for the artificial pancreas (AP). In this talk, I will outline the difficulties inherent in controlling physiological variables, the challenges with regulatory approval of such devices, and will describe a number of systems engineering algorithms we have tested in clinical experiments for the artificial pancreas. I will also point to the near term opportunities in the design of next-generation AP systems, including implantable systems, augmented sensors, and embedded algorithms.